Webinar: Case Studies Utilizing iPSC-Derived Cardiomyocytes in Drug Discovery

Sponsored by: Axiogenesis

Focused on:

  • Cardiomyocytes
  • Drug Discovery
  • Cardiac Screening

Date: 4 October

Days to go: 44

Time: 3PM London/10AM New York

Axiogenesis cardiac screening services and tools for efficient drug discovery

The most prominent issue facing pharmaceutical R&D is the continuing late-stage failures of drug candidates. Though novel technologies and screening techniques have continued to provide researchers with more information and predictive tools, getting drugs into the clinic is less efficient than it has been in the past.

The major cause for drug attrition can be attributed to safety and toxicity concerns that were not identified during preclinical development. To address these concerns, well-characterized/validated and quality controlled human induced pluripotent stem cell (hiPSC)-derived cells are now commercially available in large, quality controlled lots. These cells provide a flexible, cost-effective and, typically, more predictive and physiologically relevant cellular environment than immortalized cell lines or even primary rodent models.

One of the first to license the Yamanaka reprogramming factors, Axiogenesis has positioned itself as a leader in the commercialization and use of these hiPSC cell types for preclinical studies. Additionally, Axiogenesis has quietly established itself as a trusted CRO/assay service provider via its core competencies in preclinical cardiac liability assessment. We are a knowledgeable “center of excellence” partner providing customizable cell lines and screening services to help drive SAR, chemotype selection, etc. while at the same time de-risking toxicity/safety concerns.

Webinar attendees will gain insight into how Axiogenesis works closely with pharma, biotech and academia to provide a number of capabilities in a “one stop shop”. Turning the page from our last webinar where we described the predictivity of Axiogenesis’ hiPSC-derived cardiac and neural cells, this webinar will feature real-world testimonies of customers using our cells and services.

First, Dr. Courtney Miller from The Scripps Research Institute will present her work to drive MedChem efforts in a fascinating project using cardiomyocyte contractility as an endpoint to drive efficacy/target potency in the CNS for modulation of memories. Our second speaker will provide examples of manipulating cardiomyocytes with some novel tools to enhance electrophysiological and safety/tox assessment.

You don’t want to miss this one! Register now!

Presented by

Greg Luerman, PhD,

Technical Director, North America

Dr. Greg Luerman is the Technical Director for Axiogenesis (North America). Following his graduate studies at the University of Louisville School of Medicine, Dr. Luerman earned a Michael J Fox Foundation postdoctoral fellowship within the Pfizer Neuroscience Research Unit. There he was the biology project lead on a small molecule kinase project.

He moved on to establish multiple iPS-cardiomyocyte ion channel preclinical safety/tox and drug discovery services at ChanTest Corp. Now at Axiogenesis, Dr. Luerman oversees North American scientific project development, applications support, assay services, and regulatory body interactions.

Courtney Miller, PhD,

Associate Professor of Molecular Medicine & Neuroscience, The Scripps Research Institute

Dr. Courtney Miller is an associate professor at The Scripps Research Institute where she runs a research program focused on developing therapeutics for memory disorders, including Alzheimer's, PTSD, and drug addiction. After earning her doctorate in neurobiology at the University of California, Irvine, Dr. Miller served as scientific director of a behavioral characterization core at UAB where she lead a discovery team of scientists focused on central nervous system disorders.

She has won a Presidential Early Career Award and her research has been highlighted by The Economist, Time magazine, CBS and Discovery, with Seed Magazine proclaiming one of her discoveries to be a "Top 10 Scientific Discovery of the year."

Key Learning Objectives

  • Learn how iPS technologies are being used to drive SAR/medicinal chemistry efforts
  • See some cool new cellular tools to boost predictivity and productivity
  • Outsourcing with Axiogenesis: leave the work to the experts!
  • Xpress.4U: a quicker & much more cost effective alternative to CRISPR/patient derived models

Audience

  • VPs
  • Directors
  • Senior Scientists
  • Researchers
  • Principal Investigators
  • Group Leaders
  • Lab Heads
  • Study Directors
  • Consultants
  • Project Managers